{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T16:14:50Z","timestamp":1771344890378,"version":"3.50.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006109","name":"Vedeck\u00e1 Grantov\u00e1 Agent\u00fara M\u0160VVa\u0160 SR a SAV","doi-asserted-by":"publisher","award":["VEGA 2\/0088\/23"],"award-info":[{"award-number":["VEGA 2\/0088\/23"]}],"id":[{"id":"10.13039\/501100006109","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006109","name":"Vedeck\u00e1 Grantov\u00e1 Agent\u00fara M\u0160VVa\u0160 SR a SAV","doi-asserted-by":"publisher","award":["VEGA 2\/0087\/23"],"award-info":[{"award-number":["VEGA 2\/0087\/23"]}],"id":[{"id":"10.13039\/501100006109","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005357","name":"Agent\u00fara na Podporu V\u00fdskumu a V\u00fdvoja","doi-asserted-by":"publisher","award":["APVV-20-0183"],"award-info":[{"award-number":["APVV-20-0183"]}],"id":[{"id":"10.13039\/501100005357","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005357","name":"Agent\u00fara na Podporu V\u00fdskumu a V\u00fdvoja","doi-asserted-by":"publisher","award":["APVV-21-0215"],"award-info":[{"award-number":["APVV-21-0215"]}],"id":[{"id":"10.13039\/501100005357","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005357","name":"Agent\u00fara na Podporu V\u00fdskumu a V\u00fdvoja","doi-asserted-by":"publisher","award":["APVV-19-0212"],"award-info":[{"award-number":["APVV-19-0212"]}],"id":[{"id":"10.13039\/501100005357","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005357","name":"Agent\u00fara na Podporu V\u00fdskumu a V\u00fdvoja","doi-asserted-by":"publisher","award":["APVV-23-0482"],"award-info":[{"award-number":["APVV-23-0482"]}],"id":[{"id":"10.13039\/501100005357","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005357","name":"Agent\u00fara na Podporu V\u00fdskumu a V\u00fdvoja","doi-asserted-by":"publisher","award":["APVV-24-0471"],"award-info":[{"award-number":["APVV-24-0471"]}],"id":[{"id":"10.13039\/501100005357","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NextGenerationEU project","award":["No.09I03-03-V04-00451"],"award-info":[{"award-number":["No.09I03-03-V04-00451"]}]},{"name":"NextGenerationEU project","award":["No. 09I03-03-V02-00031"],"award-info":[{"award-number":["No. 09I03-03-V02-00031"]}]},{"name":"Research & Innovation Operational Programme funded by the ERDF","award":["ITMS project code 313021T081"],"award-info":[{"award-number":["ITMS project code 313021T081"]}]},{"DOI":"10.13039\/100010783","name":"Slovak Academy of Sciences","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100010783","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Mol Med"],"published-print":{"date-parts":[[2026,12]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>\n                      The CXCR4-CXCL12 axis is crucial for the interaction between malignant plasma cells (PC) and their microenvironment in multiple myeloma (MM). Here, we show that CXCR4 expression is upregulated in MM cell lines and PCs during both premalignant and active stages of MM, compared to normal PCs from healthy donors. The CXCR4 antagonist WZ811 reduced the viability of MM PCs and cell lines, while tumor microenvironment cells from both MM patients and healthy donors exhibited significant resistance. In vivo, WZ811 significantly reduced tumor burden and improved survival. WZ811-mediated MM cell death involved disruption of mitochondrial transmembrane potential, externalization of transmembrane phosphatidylserine, activation of caspases, increased levels of autophagic proteins, and an increase in G\n                      <jats:sub>0<\/jats:sub>\n                      \/G\n                      <jats:sub>1<\/jats:sub>\n                      phase of the cell cycle. WZ811 also eliminated the MM stem cell-like side population, though slight resistance was observed with stromal cells. Additionally, WZ811 increased levels of CXCL12 and extracellular matrix molecules collagen IV and laminin in MM cells. Combining WZ811 with anti-MM agents showed synergism with doxorubicin, dexamethasone, bortezomib, lenalidomide, and pomalidomide, while antagonism was observed with carfilzomib, supporting the clinical assessment of WZ811 in MM.\u00a0\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Key messages<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>WZ811 reduced the viability of myeloma primary cells and cell lines.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>WZ811 reduced tumor burden and improved survival in vivo xenograft model.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>WZ811 mechanisms involved apoptotic and autophagic cell death.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>WZ811 eliminated the MM stem cell-like side population.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>WZ811 synergized with DOX, DEX, BTZ, LEN, and POM.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00109-026-02650-4","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T15:38:46Z","timestamp":1771342726000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Anti-myeloma activity of the CXCR4 antagonist WZ811"],"prefix":"10.1007","volume":"104","author":[{"given":"Danka","family":"Cholujova","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikoleta","family":"Csicsatkova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zuzana","family":"Valuskova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katarina","family":"Suroviakova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Elisabeth","family":"Marinkovicova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Strizova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Sedlak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2593-569X","authenticated-orcid":false,"given":"Jana","family":"Jakubikova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,17]]},"reference":[{"key":"2650_CR1","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1038\/s41571-025-01041-x","volume":"22","author":"MA Dimopoulos","year":"2025","unstructured":"Dimopoulos MA, Terpos E, Boccadoro M, Moreau P, Mateos MV, Zweegman S, Cook G, Engelhardt M, Delforge M, Hajek R et al (2025) EHA-EMN evidence-based guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma. Nat Rev Clin Oncol 22:680\u2013700","journal-title":"Nat Rev Clin Oncol"},{"key":"2650_CR2","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1002\/ajh.27422","volume":"99","author":"SV Rajkumar","year":"2024","unstructured":"Rajkumar SV (2024) Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management. Am J Hematol 99:1802\u20131824","journal-title":"Am J Hematol"},{"key":"2650_CR3","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1002\/ajh.25627","volume":"94","author":"IM Ghobrial","year":"2019","unstructured":"Ghobrial IM, Liu CJ, Zavidij O, Azab AK, Baz R, Laubach JP, Mishima Y, Armand P, Munshi NC, Basile F et al (2019) Phase I\/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed\/refractory multiple myeloma. Am J Hematol 94:1244\u20131253","journal-title":"Am J Hematol"},{"key":"2650_CR4","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2024.2329140","volume":"56","author":"Y Li","year":"2024","unstructured":"Li Y, Qiu X, Lei Y, Zhou R (2024) G-CSF + plerixafor versus G-CSF alone mobilized hematopoietic stem cells in patients with multiple myeloma and lymphoma: a systematic review and meta-analysis. Ann Med 56:2329140","journal-title":"Ann Med"},{"key":"2650_CR5","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-025-02356-y","volume":"16","author":"Y Wang","year":"2025","unstructured":"Wang Y, Xiong Y, Gu S, Wang W, Yang Y, Liu P (2025) Clinical benefit loss in myeloma patients declining autologous stem cell transplantation: a real-world study. Discov Oncol 16:534","journal-title":"Discov Oncol"},{"key":"2650_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41389-022-00380-z","volume":"11","author":"C Giallongo","year":"2022","unstructured":"Giallongo C, Dulcamare I, Tibullo D, Del Fabro V, Vicario N, Parrinello N, Romano A, Scandura G, Lazzarino G, Conticello C et al (2022) CXCL12\/CXCR4 axis supports mitochondrial trafficking in tumor myeloma microenvironment. Oncogenesis 11:6","journal-title":"Oncogenesis"},{"key":"2650_CR7","doi-asserted-by":"crossref","unstructured":"Roccaro AM, Mishima Y, Sacco A, Moschetta M, Tai YT, Shi J, Zhang Y, Reagan MR, Huynh D, Kawano Y et al (2015) CXCR4 regulates extra-medullary myeloma through epithelial-mesenchymal-transition-like transcriptional activation. Cell Rep 12:622\u2013635","DOI":"10.1016\/j.celrep.2015.06.059"},{"key":"2650_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbo.2019.100253","volume":"17","author":"TR Ullah","year":"2019","unstructured":"Ullah TR (2019) The role of CXCR4 in multiple myeloma: cells\u2019 journey from bone marrow to beyond. J Bone Oncol 17:100253","journal-title":"J Bone Oncol"},{"key":"2650_CR9","doi-asserted-by":"publisher","DOI":"10.1177\/20406207231174304","volume":"14","author":"ZD Crees","year":"2023","unstructured":"Crees ZD, Rettig MP, DiPersio JF (2023) Innovations in hematopoietic stem-cell mobilization: a review of the novel CXCR4 inhibitor motixafortide. Ther Adv Hematol 14:20406207231174304","journal-title":"Ther Adv Hematol"},{"key":"2650_CR10","doi-asserted-by":"publisher","first-page":"47","DOI":"10.7150\/thno.5376","volume":"3","author":"B Debnath","year":"2013","unstructured":"Debnath B, Xu S, Grande F, Garofalo A, Neamati N (2013) Small molecule inhibitors of CXCR4. Theranostics 3:47\u201375","journal-title":"Theranostics"},{"key":"2650_CR11","first-page":"3812","volume":"8","author":"SH Li","year":"2016","unstructured":"Li SH, Dong WC, Fan L, Wang GS (2016) Suppression of chronic lymphocytic leukemia progression by CXCR4 inhibitor WZ811. Am J Transl Res 8:3812\u20133821","journal-title":"Am J Transl Res"},{"key":"2650_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0176057","volume":"12","author":"A Van Hout","year":"2017","unstructured":"Van Hout A, D\u2019Huys T, Oeyen M, Schols D, Van Loy T (2017) Comparison of cell-based assays for the identification and evaluation of competitive CXCR4 inhibitors. PLoS One 12:e0176057","journal-title":"PLoS One"},{"key":"2650_CR13","doi-asserted-by":"publisher","first-page":"8556","DOI":"10.1021\/jm100786g","volume":"53","author":"A Zhu","year":"2010","unstructured":"Zhu A, Zhan W, Liang Z, Yoon Y, Yang H, Grossniklaus HE, Xu J, Rojas M, Lockwood M, Snyder JP et al (2010) Dipyrimidine amines: a novel class of chemokine receptor type 4 antagonists with high specificity. J Med Chem 53:8556\u20138568","journal-title":"J Med Chem"},{"key":"2650_CR14","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1124\/pr.58.3.10","volume":"58","author":"TC Chou","year":"2006","unstructured":"Chou TC (2006) Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58:621\u2013681","journal-title":"Pharmacol Rev"},{"key":"2650_CR15","first-page":"200","volume":"91","author":"I Vande Broek","year":"2006","unstructured":"Vande Broek I, Leleu X, Schots R, Facon T, Vanderkerken K, Van Camp B, Van Riet I (2006) Clinical significance of chemokine receptor (CCR1, CCR2 and CXCR4) expression in human myeloma cells: the association with disease activity and survival. Haematologica 91:200\u2013206","journal-title":"Haematologica"},{"key":"2650_CR16","doi-asserted-by":"crossref","unstructured":"Jakubikova J, Cholujova D, Beke G, Hideshima T, Klucar L, Leiba M, Jamroziak K, Richardson PG, Kastritis E, Dorfman DM et al (2023) Heterogeneity of B cell lymphopoiesis in patients with premalignant and active myeloma. JCI Insight 8:e159924","DOI":"10.1172\/jci.insight.159924"},{"key":"2650_CR17","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1038\/onc.2015.139","volume":"35","author":"F Guo","year":"2016","unstructured":"Guo F, Wang Y, Liu J, Mok SC, Xue F, Zhang W (2016) CXCL12\/CXCR4: a symbiotic bridge linking cancer cells and their stromal neighbors in oncogenic communication networks. Oncogene 35:816\u2013826","journal-title":"Oncogene"},{"key":"2650_CR18","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.18632\/oncotarget.1497","volume":"4","author":"J Abdi","year":"2013","unstructured":"Abdi J, Chen G, Chang H (2013) Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms. Oncotarget 4:2186\u20132207","journal-title":"Oncotarget"},{"key":"2650_CR19","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1158\/0008-5472.CAN-04-1687","volume":"65","author":"AC Zannettino","year":"2005","unstructured":"Zannettino AC, Farrugia AN, Kortesidis A, Manavis J, To LB, Martin SK, Diamond P, Tamamura H, Lapidot T, Fujii N et al (2005) Elevated serum levels of stromal-derived factor-1alpha are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients. Cancer Res 65:1700\u20131709","journal-title":"Cancer Res"},{"key":"2650_CR20","doi-asserted-by":"publisher","first-page":"5720","DOI":"10.1182\/blood-2008-08-174946","volume":"113","author":"JF DiPersio","year":"2009","unstructured":"DiPersio JF, Stadtmauer EA, Nademanee A, Micallef IN, Stiff PJ, Kaufman JL, Maziarz RT, Hosing C, Fruehauf S, Horwitz M et al (2009) Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 113:5720\u20135726","journal-title":"Blood"},{"key":"2650_CR21","doi-asserted-by":"publisher","first-page":"23890","DOI":"10.18632\/oncotarget.25156","volume":"9","author":"G Fouquet","year":"2018","unstructured":"Fouquet G, Guidez S, Richez V, Stoppa AM, Le Tourneau C, Macro M, Gruchet C, Bobin A, Moya N, Syshenko T et al (2018) Phase I dose-escalation study of F50067, a humanized anti-CXCR4 monoclonal antibody alone and in combination with lenalidomide and low-dose dexamethasone, in relapsed or refractory multiple myeloma. Oncotarget 9:23890\u201323899","journal-title":"Oncotarget"},{"key":"2650_CR22","doi-asserted-by":"crossref","unstructured":"Ghobrial IM, Liu CJ, Redd RA, Perez RP, Baz R, Zavidij O, Sklavenitis-Pistofidis R, Richardson PG, Anderson KC, Laubach J et al (2020) A phase Ib\/II trial of the first-in-class anti-CXCR4 antibody ulocuplumab in combination with lenalidomide or bortezomib plus dexamethasone in relapsed multiple myeloma. Clin Cancer Res 26:344\u2013353","DOI":"10.1158\/1078-0432.CCR-19-0647"},{"key":"2650_CR23","doi-asserted-by":"crossref","unstructured":"Peled A, Abraham M, Avivi I, Rowe JM, Beider K, Wald H, Tiomkin L, Ribakovsky L, Riback Y, Ramati Y et al (2014) The high-affinity CXCR4 antagonist BKT140 is safe and induces a robust mobilization of human CD34+ cells in patients with multiple myeloma. Clin Cancer Res 20:469\u2013479","DOI":"10.1158\/1078-0432.CCR-13-1302"},{"key":"2650_CR24","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.2967\/jnumed.111.098798","volume":"52","author":"E Gourni","year":"2011","unstructured":"Gourni E, Demmer O, Schottelius M, D\u2019Alessandria C, Schulz S, Dijkgraaf I, Schumacher U, Schwaiger M, Kessler H, Wester HJ (2011) PET of CXCR4 expression by a (68)Ga-labeled highly specific targeted contrast agent. J Nucl Med 52:1803\u20131810","journal-title":"J Nucl Med"},{"key":"2650_CR25","doi-asserted-by":"crossref","unstructured":"Herrmann K, Schottelius M, Lapa C, Osl T, Poschenrieder A, Hanscheid H, Luckerath K, Schreder M, Bluemel C, Knott M et al (2016) First-in-human experience of CXCR4-directed endoradiotherapy with 177Lu- and 90Y-labeled pentixather in advanced-stage multiple myeloma with extensive intra- and extramedullary disease. J Nucl Med 57:248\u2013251","DOI":"10.2967\/jnumed.115.167361"},{"key":"2650_CR26","doi-asserted-by":"crossref","unstructured":"Kashyap MK, Amaya-Chanaga CI, Kumar D, Simmons B, Huser N, Gu Y, Hallin M, Lindquist K, Yafawi R, Choi MY et al (2017) Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemia. J Hematol Oncol 10:112","DOI":"10.1186\/s13045-017-0435-x"},{"key":"2650_CR27","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/S1470-2045(20)30680-X","volume":"22","author":"JP Laubach","year":"2021","unstructured":"Laubach JP, Schjesvold F, Mariz M, Dimopoulos MA, Lech-Maranda E, Spicka I, Hungria VTM, Shelekhova T, Abdo A, Jacobasch L et al (2021) Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study. Lancet Oncol 22:142\u2013154","journal-title":"Lancet Oncol"},{"key":"2650_CR28","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1038\/leu.2017.5","volume":"31","author":"H Ludwig","year":"2017","unstructured":"Ludwig H, Weisel K, Petrucci MT, Leleu X, Cafro AM, Garderet L, Leitgeb C, Foa R, Greil R, Yakoub-Agha I et al (2017) Olaptesed pegol, an anti-CXCL12\/SDF-1 Spiegelmer, alone and with bortezomib-dexamethasone in relapsed\/refractory multiple myeloma: a phase IIa study. Leukemia 31:997\u20131000","journal-title":"Leukemia"},{"key":"2650_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0150585","volume":"11","author":"SB Peng","year":"2016","unstructured":"Peng SB, Zhang X, Paul D, Kays LM, Ye M, Vaillancourt P, Dowless M, Stancato LF, Stewart J, Uhlik MT et al (2016) Inhibition of CXCR4 by LY2624587, a fully humanized anti-CXCR4 antibody induces apoptosis of hematologic malignancies. PLoS ONE 11:e0150585","journal-title":"PLoS ONE"},{"key":"2650_CR30","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1258\/ebm.2011.010345","volume":"236","author":"SP Kawatkar","year":"2011","unstructured":"Kawatkar SP, Yan M, Gevariya H, Lim MY, Eisold S, Zhu X, Huang Z, An J (2011) Computational analysis of the structural mechanism of inhibition of chemokine receptor CXCR4 by small molecule antagonists. Exp Biol Med (Maywood) 236:844\u2013850","journal-title":"Exp Biol Med (Maywood)"},{"key":"2650_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2023.115753","volume":"261","author":"T Gaines","year":"2023","unstructured":"Gaines T, Garcia F, Virani S, Liang Z, Yoon Y, Oum YH, Shim H, Mooring SR (2023) Corrigendum to \u201cSynthesis and evaluation of 2,5-furan, 2,5-thiophene and 3,4-thiophene-based derivatives as CXCR4 inhibitors\u201d [Eur. J. Med. Chem. 181 (2019) 111562]. Eur J Med Chem 261:115753","journal-title":"Eur J Med Chem"},{"key":"2650_CR32","doi-asserted-by":"publisher","first-page":"5655","DOI":"10.1021\/jm070679i","volume":"50","author":"W Zhan","year":"2007","unstructured":"Zhan W, Liang Z, Zhu A, Kurtkaya S, Shim H, Snyder JP, Liotta DC (2007) Discovery of small molecule CXCR4 antagonists. J Med Chem 50:5655\u20135664","journal-title":"J Med Chem"},{"key":"2650_CR33","volume":"2022","author":"YA Zhang","year":"2022","unstructured":"Zhang YA, Yang X, Yao J, Ren Y, Liu P (2022) Identification of CXCR4 upregulation in diffuse large B-cell lymphoma associated with prognostic significance and clinicopathological characteristics. Dis Markers 2022:3276925","journal-title":"Dis Markers"},{"key":"2650_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.543066","volume":"8","author":"AY Streletskaia","year":"2020","unstructured":"Streletskaia AY, Senichkin VV, Prikazchikova TA, Zatsepin TS, Zhivotovsky B, Kopeina GS (2020) Upregulation of Mcl-1S causes cell-cycle perturbations and DNA damage accumulation. Front Cell Dev Biol 8:543066","journal-title":"Front Cell Dev Biol"},{"key":"2650_CR35","doi-asserted-by":"crossref","unstructured":"Dalle Carbonare L, Minoia A, Vareschi A, Piritore FC, Zouari S, Gandini A, Meneghel M, Elia R, Lorenzi P, Antoniazzi F et al (2024) Exploring the interplay of RUNX2 and CXCR4 in melanoma progression. Cells 13:408","DOI":"10.3390\/cells13050408"},{"key":"2650_CR36","doi-asserted-by":"crossref","unstructured":"Iriondo MN, Etxaniz A, Varela YR, Ballesteros U, Lazaro M, Valle M, Fracchiolla D, Martens S, Montes LR, Goni FM et al (2023) Effect of ATG12-ATG5-ATG16L1 autophagy E3-like complex on the ability of LC3\/GABARAP proteins to induce vesicle tethering and fusion. Cell Mol Life Sci 80:56","DOI":"10.1007\/s00018-023-04704-z"},{"key":"2650_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2012.120","volume":"3","author":"M Baritaud","year":"2012","unstructured":"Baritaud M, Cabon L, Delavallee L, Galan-Malo P, Gilles ME, Brunelle-Navas MN, Susin SA (2012) AIF-mediated caspase-independent necroptosis requires ATM and DNA-PK-induced histone H2AX Ser139 phosphorylation. Cell Death Dis 3:e390","journal-title":"Cell Death Dis"},{"key":"2650_CR38","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1091\/mbc.e09-07-0618","volume":"21","author":"ME Gagou","year":"2010","unstructured":"Gagou ME, Zuazua-Villar P, Meuth M (2010) Enhanced H2AX phosphorylation, DNA replication fork arrest, and cell death in the absence of Chk1. Mol Biol Cell 21:739\u2013752","journal-title":"Mol Biol Cell"},{"key":"2650_CR39","doi-asserted-by":"crossref","unstructured":"Jung SH, Won KJ, Lee KP, Lee DH, Yu S, Lee DY, Seo EH, Kang H, Park ES, Kim HJ et al (2014) DJ-1 protein regulates CD3+ T cell migration via overexpression of CXCR4 receptor. Atherosclerosis 235:503\u2013509","DOI":"10.1016\/j.atherosclerosis.2014.05.955"},{"key":"2650_CR40","doi-asserted-by":"crossref","unstructured":"Zhou Y, Zhang B, Li C, Huang X, Cheng H, Bao X, Zhao F, Cheng Q, Yue S, Han J et al (2019) Megakaryocytes participate in the occurrence of bleomycin-induced pulmonary fibrosis. Cell Death Dis 10:648","DOI":"10.1038\/s41419-019-1903-8"},{"key":"2650_CR41","doi-asserted-by":"publisher","first-page":"929","DOI":"10.7150\/jca.23042","volume":"9","author":"TA Werner","year":"2018","unstructured":"Werner TA, Forster CM, Dizdar L, Verde PE, Raba K, Schott M, Knoefel WT, Krieg A (2018) CXCR4\/CXCR7\/CXCL12-axis in follicular thyroid carcinoma. J Cancer 9:929\u2013940","journal-title":"J Cancer"},{"key":"2650_CR42","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1002\/cbin.11024","volume":"42","author":"CH Zheng","year":"2018","unstructured":"Zheng CH, Chen XM, Zhang FB, Zhao C, Tu SS (2018) Inhibition of CXCR4 regulates epithelial mesenchymal transition of NSCLC via the Hippo-YAP signaling pathway. Cell Biol Int 42:1386\u20131394","journal-title":"Cell Biol Int"},{"key":"2650_CR43","first-page":"5481","volume":"12","author":"J Xu","year":"2020","unstructured":"Xu J, Li N, Deng W, Luo S (2020) Long noncoding RNA FER1L4 suppresses proliferation, invasion, migration and lymphatic metastasis of gastric cancer cells through inhibiting the Hippo-YAP signaling pathway. Am J Transl Res 12:5481\u20135495","journal-title":"Am J Transl Res"},{"key":"2650_CR44","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1080\/10428194.2017.1379077","volume":"59","author":"ZZ Xu","year":"2018","unstructured":"Xu ZZ, Shen JK, Zhao SQ, Li JM (2018) Clinical significance of chemokine receptor CXCR4 and mammalian target of rapamycin (mTOR) expression in patients with diffuse large B-cell lymphoma. Leuk Lymphoma 59:1451\u20131460","journal-title":"Leuk Lymphoma"},{"key":"2650_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-05421-4","volume":"13","author":"O Darawshi","year":"2022","unstructured":"Darawshi O, Muz B, Naamat SG, Praveen B, Mahameed M, Goldberg K, Dipta P, Shmuel M, Forno F, Boukeileh S et al (2022) An mTORC1 to HRI signaling axis promotes cytotoxicity of proteasome inhibitors in multiple myeloma. Cell Death Dis 13:969","journal-title":"Cell Death Dis"},{"key":"2650_CR46","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.clml.2017.09.020","volume":"18","author":"S Yaccoby","year":"2018","unstructured":"Yaccoby S (2018) Two states of myeloma stem cells. Clin Lymphoma Myeloma Leuk 18:38\u201343","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2650_CR47","doi-asserted-by":"publisher","first-page":"4409","DOI":"10.1182\/blood-2010-02-267344","volume":"117","author":"J Jakubikova","year":"2011","unstructured":"Jakubikova J, Adamia S, Kost-Alimova M, Klippel S, Cervi D, Daley JF, Cholujova D, Kong SY, Leiba M, Blotta S et al (2011) Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications. Blood 117:4409\u20134419","journal-title":"Blood"},{"key":"2650_CR48","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/sj.leu.2403184","volume":"18","author":"MZ Ratajczak","year":"2004","unstructured":"Ratajczak MZ, Kucia M, Reca R, Majka M, Janowska-Wieczorek A, Ratajczak J (2004) Stem cell plasticity revisited: CXCR4-positive cells expressing mRNA for early muscle, liver and neural cells \u2018hide out\u2019 in the bone marrow. Leukemia 18:29\u201340","journal-title":"Leukemia"},{"key":"2650_CR49","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/B978-0-12-411638-2.00002-1","volume":"124","author":"S Chatterjee","year":"2014","unstructured":"Chatterjee S, Behnam Azad B, Nimmagadda S (2014) The intricate role of CXCR4 in cancer. Adv Cancer Res 124:31\u201382","journal-title":"Adv Cancer Res"},{"key":"2650_CR50","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1016\/j.leukres.2008.09.018","volume":"33","author":"AM Oliveira","year":"2009","unstructured":"Oliveira AM, Maria DA, Metzger M, Linardi C, Giorgi RR, Moura F, Martinez GA, Bydlowski SP, Novak EM (2009) Thalidomide treatment down-regulates SDF-1alpha and CXCR4 expression in multiple myeloma patients. Leuk Res 33:970\u2013973","journal-title":"Leuk Res"}],"container-title":["Journal of Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00109-026-02650-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00109-026-02650-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00109-026-02650-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T15:38:50Z","timestamp":1771342730000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00109-026-02650-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,17]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["2650"],"URL":"https:\/\/doi.org\/10.1007\/s00109-026-02650-4","relation":{},"ISSN":["0946-2716","1432-1440"],"issn-type":[{"value":"0946-2716","type":"print"},{"value":"1432-1440","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,17]]},"assertion":[{"value":"25 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Human Ethics Committee of the Biomedical Research Center in Bratislava, Slovakia, under reference number Myelom 001. All patient and healthy donor samples were obtained following written informed consent, consistent with the Declaration of Helsinki protocol. Clinical trial number: not applicable. This study was approved by the Institutional Animal Ethics committee of animal research of the Biomedical Research Center in Bratislava, Slovakia and State Veterinary and Food Administration of the Slovak Republic with reference number myelom. In accordance with institutional guidelines and approved protocols, in vivo experiments utilizing a MM xenograft mouse model were conducted.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"45"}}